More recently, the development of anti-CD19 chimeric antigen receptor (CAR) T-cell therapy achieved a major milestone in the treatment of R/R B-ALL and added another option to the arsenal against B-ALL. Here, CD19 is linked to acute lymphoblastic leukemia.